Corcept Therapeutics Incorporated
Common Stock · USD · NASDAQ
Price
$69.46
Cap
$466.67B
Earnings
—
30d Trend
+49.2%
69% annualised over 90 days
BRAIN47 SIGNAL
Raw weighted: 37×Macro 0.99 (−1%)=37
RISK
QUALITY
MOMENTUM
TECHNICAL
FUNDAMENTALS
Macro: neutral (×0.99) - Fear/Greed: 65 (Greed) - Data: 100%
BRAIN47 HORIZON ANALYSIS
5-10 day swing — momentum continuation
BRAIN47'S ASSESSMENT
I rate Corcept Therapeutics Incorporated at 37/100 — a WEAK reading on the Brain47 Signal. The strongest factor is technical at 60/100. I classify this as a speculative position with the strongest thesis on a short-term horizon.
PAST PERFORMANCE
1 MONTH
+43.0%
3 MONTHS
+86.7%
12 MONTHS
-14.2%
Trailing returns — past performance, not a projection.
DETAILED ANALYSIS
5-10 day swing — momentum continuation. Technical (60) and Quality (52) are the primary strengths. I note that momentum is the weakest area at 9/100 — this warrants monitoring. Historical volatility is elevated at 69%. I classify this as a speculative position — elevated volatility at 69% and asymmetric payoff potential define the opportunity.
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.